EpigenCare matches skin types with best product

Epigenomics and digital biotechnology company EpigenCare has revealed the world’s first project for personalised skincare based on epigenetic and blockchain technology. The biotechnology company’s digital platform will connect consumers with skincare companies using a scientific matching algorithm based on the consumer’s epigenetic profile and a product’s active ingredients.

The company developed a personal epigenomics test to generate epigenetic skin profiles that correlate with key skin quality indicators, for example, ageing, elasticity and moisture retention. The DNA samples, collected at home, are posted to EpigenCare’s facilities for testing via a proprietary next-generation sequencing-based application.

The model will prompt skincare companies to market and produce products with more scientific transparency and consumer personalisation. 

Comprehensive index and matching algorithm

The company is indexing the ingredients of thousands of skincare products, ranging from name brand to boutique. The matching algorithm will then select the ingredients that would best for the customer’s skin. 

Through EpigenCare’s web platform, called “The EpigenCare Network”, skincare companies will be able to use the scientific-matching mechanism of the recommendation engine. These companies will target epigenetic profile segments with the opportunity to place their auto-screened products in the recommendation section of the consumer’s test results. 

The model will prompt skincare companies to market and produce products with more scientific transparency and consumer personalisation. 

The company’s industry advisor, Richard Wildnauer, former CEO of NeoStrata and VP at Johnson & Johnson, expressed his enthusiasm for the innovation. “This revolutionary business model promises to uniquely take advantage of the rapidly developing fields of epigenetics and blockchain,” he said, “to develop a database to solve the problems of product selection for personalised targeted skin care. It reduces the costs and frustrations of multiple product trials by consumers, provides cosmetic companies with another tool to guide product development and provides a basis for monetisation by the consumer participants and EpigenCare.”